用于治愈导向临床试验中测量 HIV 储存库大小的建议。
Recommendations for measuring HIV reservoir size in cure-directed clinical trials.
机构信息
The Wistar Institute, Philadelphia, PA, USA.
VA San Diego Healthcare System and University of California, San Diego, CA, USA.
出版信息
Nat Med. 2020 Sep;26(9):1339-1350. doi: 10.1038/s41591-020-1022-1. Epub 2020 Sep 7.
Abstract
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
摘要
治疗策略正在临床测试中，旨在消灭潜伏的 HIV 储库，或在没有抗逆转录病毒治疗的情况下实现病毒学控制。要实现这一目标，就需要就如何最好地衡量在停止抗逆转录病毒治疗后有潜力引起病毒反弹的持续感染细胞数量达成共识，从而评估体内治愈导向策略的结果。目前的测量方法评估了 HIV 前病毒及其功能的各个方面，并产生了不同的结果。在这里，我们提供了 BEAT-HIV Martin Delaney 合作实验室的建议，即在 HIV 治愈导向临床试验中应优先考虑哪些病毒测量。
相似文献
1
Recommendations for measuring HIV reservoir size in cure-directed clinical trials.用于治愈导向临床试验中测量 HIV 储存库大小的建议。
Nat Med. 2020 Sep;26(9):1339-1350. doi: 10.1038/s41591-020-1022-1. Epub 2020 Sep 7.
2
VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.VIP-SPOT：一种创新的测定方法，用于定量监测治愈策略中 HIV-1 储存库的产生。
mBio. 2021 Jun 29;12(3):e0056021. doi: 10.1128/mBio.00560-21. Epub 2021 Jun 22.
3
Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.长期使用马拉维若可使潜伏的 HIV 在体内重新激活，但不能预防无抗逆转录病毒治疗的病毒反弹。
Sci Rep. 2020 Dec 18;10(1):22286. doi: 10.1038/s41598-020-79002-w.
4
HIV reservoirs as obstacles and opportunities for an HIV cure.HIV 储库——HIV 治愈的障碍与机遇。
Nat Immunol. 2015 Jun;16(6):584-9. doi: 10.1038/ni.3152.
5
Targeting the Latent Reservoir for HIV-1.针对 HIV-1 的潜伏储库。
Immunity. 2018 May 15;48(5):872-895. doi: 10.1016/j.immuni.2018.04.030.
6
HIV-1 Reservoirs During Suppressive Therapy.抑制性治疗期间的HIV-1储存库
Trends Microbiol. 2016 May;24(5):345-355. doi: 10.1016/j.tim.2016.01.006. Epub 2016 Feb 12.
7
Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.从感染患者中根除 HIV 的策略：消除潜伏的前病毒库。
Cell Mol Life Sci. 2019 Sep;76(18):3583-3600. doi: 10.1007/s00018-019-03156-8. Epub 2019 May 25.
8
HIV reservoirs and strategies for eradication.HIV 储库与清除策略。
Curr HIV/AIDS Rep. 2012 Mar;9(1):5-15. doi: 10.1007/s11904-011-0108-2.
9
10
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.马拉维若与潜伏 HIV-1 再激活有关，通过抑制性抗逆转录病毒治疗的 HIV 感染者静息 CD4 T 细胞中 NF-κB 的激活。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01931-17. Print 2018 May 1.
引用本文的文献
1
Duplex digital PCR assay on microfluidic chamber arrays for total HIV DNA reservoir quantification in persons with HIV.用于定量检测HIV感染者体内总HIV DNA储存库的微流控芯片阵列双链数字PCR检测法
Sci Rep. 2025 Aug 27;15(1):31658. doi: 10.1038/s41598-025-17392-5.
2
Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.原发性HIV-1感染期间启动的短期抗逆转录病毒治疗对病毒持续存在的长期影响。
Nat Commun. 2025 Jul 30;16(1):6989. doi: 10.1038/s41467-025-62362-0.
3
Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.“乘客”假说在HIV病毒库持久性及治愈方面的应用与局限性
J Virol. 2025 Jul 22;99(7):e0071425. doi: 10.1128/jvi.00714-25. Epub 2025 Jun 4.
4
A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients.一种首创的Bcl-2/Bcl-xL双降解剂可逆转HIV潜伏期并使患者的体外病毒储存库最小化。
Int J Mol Sci. 2025 Mar 19;26(6):2772. doi: 10.3390/ijms26062772.
5
Studies of young adults with perinatal HIV infection provide new clues for HIV cure.对围产期感染艾滋病毒的年轻人的研究为治愈艾滋病毒提供了新线索。
AIDS. 2025 Mar 15;39(4):457-458. doi: 10.1097/QAD.0000000000004107. Epub 2025 Feb 27.
6
The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era.在当前抗逆转录病毒时代检测、量化和表征病毒储存库所面临的挑战。
NeuroImmune Pharm Ther. 2024 Dec 5;3(3-4):211-219. doi: 10.1515/nipt-2024-0017. eCollection 2024 Sep.
7
Current methods for detecting and assessing HIV-1 antibody resistance.检测和评估HIV-1抗体耐药性的当前方法。
Front Immunol. 2025 Jan 6;15:1443377. doi: 10.3389/fimmu.2024.1443377. eCollection 2024.
8
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.用于广泛中和抗HIV-1抗体的中和敏感性筛选试验的评估及真实世界经验
J Infect Dis. 2025 Feb 20;231(2):424-434. doi: 10.1093/infdis/jiae486.
9
Soluble markers of viral rebound and post-treatment HIV control.病毒反弹和治疗后HIV控制的可溶性标志物。
Curr Opin HIV AIDS. 2025 Jan 1;20(1):61-69. doi: 10.1097/COH.0000000000000889. Epub 2024 Sep 25.
10
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study.抗 PD-L1 抗体 ASC22 联合组蛋白去乙酰化酶抑制剂西达本胺作为无 ART 的病毒学控制的“休克和杀伤”策略：一项 II 期单臂研究。
Signal Transduct Target Ther. 2024 Sep 9;9(1):231. doi: 10.1038/s41392-024-01943-9.
本文引用的文献
1
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.完整的人类免疫缺陷病毒 (HIV) 储库通过完整原病毒 DNA 检测来估计，与抑制性抗逆转录病毒治疗期间血液中总 DNA 和整合 DNA 的水平相关。
Clin Infect Dis. 2021 Feb 1;72(3):495-498. doi: 10.1093/cid/ciaa809.
2
A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption.在分析性治疗中断后出现病毒学反弹时，可鉴定出一小部分巨噬细胞嗜性 HIV-1 变异体。
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9981-9990. doi: 10.1073/pnas.1917034117. Epub 2020 Apr 16.
3
Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.细胞相关 HIV-1 RNA 预测临时早期 ART 中断后病毒反弹和疾病进展。
JCI Insight. 2020 Mar 26;5(6):134196. doi: 10.1172/jci.insight.134196.
4
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.单独抗逆转录病毒疗法与抗逆转录病毒疗法联合“踢杀”策略对近期感染 HIV 参与者的 HIV 储存库测量的影响（RIVER 试验）：一项 2 期随机试验。
Lancet. 2020 Mar 14;395(10227):888-898. doi: 10.1016/S0140-6736(19)32990-3. Epub 2020 Feb 19.
5
Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.在接受抑制性抗逆转录病毒治疗的 HIV-1 感染者中，完整和有缺陷的前病毒 DNA 的差异衰减。
JCI Insight. 2020 Feb 27;5(4):132997. doi: 10.1172/jci.insight.132997.
6
Defective HIV-1 proviruses produce viral proteins.缺陷型 HIV-1 前病毒可产生病毒蛋白。
Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3704-3710. doi: 10.1073/pnas.1917876117. Epub 2020 Feb 6.
7
Different human resting memory CD4 T cell subsets show similar low inducibility of latent HIV-1 proviruses.不同的人静息记忆 CD4 T 细胞亚群显示潜伏 HIV-1 前病毒相似的低诱导性。
Sci Transl Med. 2020 Jan 29;12(528). doi: 10.1126/scitranslmed.aax6795.
8
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint.血浆和抗体糖组学生物标志物与 HIV 反弹时间和病毒基准的关系。
AIDS. 2020 Apr 1;34(5):681-686. doi: 10.1097/QAD.0000000000002476.
9
HIV persists throughout deep tissues with repopulation from multiple anatomical sources.HIV 存在于深部组织中，并从多个解剖部位重新定植。
J Clin Invest. 2020 Apr 1;130(4):1699-1712. doi: 10.1172/JCI134815.
10
Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors.联合 HIV-1 序列和整合位点分析可提供病毒动力学信息，并允许重建复制病毒的祖先。
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25891-25899. doi: 10.1073/pnas.1910334116. Epub 2019 Nov 27.
Zotero 插件